文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

危重症成人患者补充维生素D及其代谢物:随机对照试验的系统评价与Meta分析更新

Administration of vitamin D and its metabolites in critically ill adult patients: an updated systematic review with meta-analysis of randomized controlled trials.
PubMed 文献 · Crit Care · 2022-09-06
一句话结论16项RCT共2449例危重症成人补充维生素D及其代谢物与总体死亡率降低相关(RR 0.78,95%CI 0.62-0.97,p=0.03),但异质性和证据确定性限制其普遍适用性。

该系统评价与Meta分析检索截至2022年2月9日的主要数据库,纳入16项随机对照试验共2449例危重症成人患者,干预组接受维生素D或其代谢物。结果显示补充维生素D与总体死亡率降低(RR 0.78,95%CI 0.62-0.97,p=0.03;I²=30%)、ICU住院时间缩短(平均差-3.13天,95%CI -5.36至-0.89,n=1250,p=0.006;I²=70%)和机械通气时间缩短(平均差-5.07天,95%CI -7.42至-2.73,n=572,p<0.0001;I²=54%)相关。肠外给药对总体死亡率的影响大于肠内给药(亚组差异检验p=0.04),但肠外给药亚组研究质量较低。基于基线维生素D水平的亚组无差异。作者认为危重症患者补充维生素D可能降低死亡率,肠外给药可能影响更大,但异质性和证据确定性限制结果的普遍性。

要点

  • 16项RCT共2449例危重症成人补充维生素D及其代谢物与总体死亡率降低相关(RR 0.78,95%CI 0.62-0.97,p=0.03;I²=30%)。
  • 补充维生素D与ICU住院时间缩短相关(12项研究,平均差-3.13天,95%CI -5.36至-0.89,n=1250,p=0.006;I²=70%)。
  • 补充维生素D与机械通气时间缩短相关(9项研究,平均差-5.07天,95%CI -7.42至-2.73,n=572,p<0.0001;I²=54%)。
  • 肠外给药对总体死亡率的影响大于肠内给药(亚组差异检验p=0.04),但肠外给药亚组研究质量较低。
  • 基于基线维生素D水平的亚组间无差异;作者认为异质性和证据确定性限制结果的普遍性。

适用人群与场景

  • 成人危重症患者,纳入随机对照试验的干预组接受维生素D或其代谢物。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入16项随机对照试验,共2449例危重症成人患者。
  • 总体死亡率:16项研究,风险比0.78(95%CI 0.62-0.97),p=0.03,I²=30%。
  • ICU住院时间:12项研究,平均差-3.13天(95%CI -5.36至-0.89),n=1250,p=0.006,I²=70%。
  • 机械通气时间:9项研究,平均差-5.07天(95%CI -7.42至-2.73),n=572,p<0.0001,I²=54%。
  • 给药途径亚组:肠外给药对总体死亡率的影响大于肠内给药(亚组差异检验p=0.04),但肠外给药亚组研究质量较低。
  • 基线维生素D水平亚组:无亚组差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析。
  • 局限:异质性和证据确定性限制结果的普遍性;肠外给药亚组研究质量较低。

对床旁实践的改变

  • 作者认为危重症患者补充维生素D可能降低死亡率,肠外给药可能对死亡率影响更大。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The clinical significance of vitamin D administration in critically ill patients remains inconclusive. The purpose of this systematic review with meta-analysis was to investigate the effect of vitamin D and its metabolites on major clinical outcomes in critically ill patients, including a subgroup analysis based on vitamin D status and route of vitamin D administration.

METHODS: Major databases were searched through February 9, 2022. Randomized controlled trials of adult critically ill patients with an intervention group receiving vitamin D or its metabolites were included. Random-effect meta-analyses were performed to estimate the pooled risk ratio (dichotomized outcomes) or mean difference (continuous outcomes). Risk of bias assessment included the Cochrane tool for assessing risk of bias in randomized trials.

RESULTS: Sixteen randomized clinical trials with 2449 patients were included. Vitamin D administration was associated with lower overall mortality (16 studies: risk ratio 0.78, 95% confidence interval 0.62-0.97, p = 0.03; I2 = 30%), reduced intensive care unit length of stay (12 studies: mean difference - 3.13 days, 95% CI - 5.36 to - 0.89, n = 1250, p = 0.006; I2 = 70%), and shorter duration of mechanical ventilation (9 studies: mean difference - 5.07 days, 95% CI - 7.42 to - 2.73, n = 572, p < 0.0001; I2 = 54%). Parenteral administration was associated with a greater effect on overall mortality than enteral administration (test of subgroup differences, p = 0.04), whereas studies of parenteral subgroups had lower quality. There were no subgroup differences based on baseline vitamin D levels.

CONCLUSIONS: Vitamin D supplementation in critically ill patients may reduce mortality. Parenteral administration might be associated with a greater impact on mortality. Heterogeneity and assessed certainty among the studies limits the generalizability of the results.

TRIAL REGISTRATION: PROSPERO international prospective database of systematic reviews (CRD42021256939-05 July 2021).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Menger J, Lee ZY, Notz Q, et al. Administration of vitamin D and its metabolites in critically ill adult patients: an updated systematic review with meta-analysis of randomized controlled trials. Crit Care. 2022. PMID: 36068584. doi:10.1186/s13054-022-04139-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。